参一胶囊联合多西紫杉醇同步放射治疗老年人非小细胞肺癌疗效观察

Efficacy of gensenoside-Rg3 combined with synchronous treatment of docetaxel and radiation in elderly patients with non-small cell lung cancer

目的 评价参一胶囊联合多西紫杉醇同步放射治疗老年非小细胞肺癌（NSCLC）的疗效和不良反应. 方法 按数字表法随机将62例老年NSCLC患者分为2组,治疗组32例给予放疗同时静脉滴注多西紫杉醇并口服参一胶囊,对照组30例给予放疗同时静脉滴注多西紫杉醇,分别观察两组的客观有效率（ORR）、疾病控制率（DCR）、远期生存率及出现的不良反应. 结果 治疗组和对照组客观有效率分别为90.6％、83.3％,疾病控制率分别为96.9％、90.0％,两组差异无统计学意义（P＞0.05）;治疗组与对照组中位生存期（OS）分别为1 7个月、10个月,1、2、3年生存率分别为56.3％、49.6％、27.5％与43.3％、25.0％、15.0％,两组差异有统计学意义（x2=4.19,P=0.04）;两组常见不良反应为骨髓抑制、消化道反应、脱发、乏力、关节酸等,无因严重不良反应停药,两组患者在不良反应发生率方面差异无统计学意义（P＞0.05）. 结论 参一胶囊联合多西紫杉醇同步放射治疗老年NSCLC,能够延长生存时间,提高生活质量,改善预后,且不良反应无明显增加.

Objective To evaluate efficacy and adverse reactions of gensenoside Rg 3 combined with synchronous docetaxel and radiation treatment in elderly patients with non-small cell lung cancer （NSCLC）.Methods 62 elderly patients with NSCLC were randomly divided into 2 groups：treatment group （n=32） were treated with radiotherapy and intravenous infusion of docetaxel and oral gensenoside-Rg3 at the same time,control group （n =30） were treated with radiotherapy and intravenous infusion of docetaxel at the same time.Objective response rate （ORR）,disease control rate （DCR）,the long term survival and adverse reactions were observed and compared between the two groups.Results The objective response rate and the disease control rate in treatment and control groups were 90.6％ versus 83.3％ and 96.9％ versus 90.0％ respectively,and the differences were not statistically significant （both P＞0.05）.Median overall survival （OS） time and 1-,2-and 3-year survival rates in treatment and control groups were 17 months versus 10 months,56.3％ versus 43.3％,49.6％ versus 25.0％,and 27.5％ versus 15.0％,respectively,and the differences were statistically significant （x2 =4.19,P 0.04）.The common adverse reactions in the two groups were myelosuppression,gastrointestinal reaction,hair loss,fatigue,joint sore.No one discontinued the treatment due to serious adverse reactions.There was no significant difference in the incidence of adverse reactions between the two groups （P＞0.05）.Conclusions The gensenoside-Rg3 combined with synchronous treatment with docetaxel and radiation for elderly patients with NSCLC can prolong the survival time,improve quality of life and the prognosis with no significant increase in adverse reactions.